Minutes

Meeting of the Scientific Committee on Consumer Safety (SCCS) WG on Methodologies

31 August 2017, Luxembourg

1. Approval of the agenda, minutes and declaration of interests

The Chair welcomed the participants and in particular external experts and observers invited. The agenda was adopted. The minutes of the previous meeting held on 3 May on BenchMark Dose approach (BMD) were published on the website on 11 May.

The Chair invited participants to declare any interest regarding matters on the agenda. None of the participants declared any interest conflicting with the matter on the agenda.

2. Nature of the meeting

This is a regular meeting of the working group.

3. EXTERNAL session (with external experts and observers)

3.1 inhalation exposure assessment

- Dr. Anthony Bowden (Unilever - representing Cosmetics Europe) – made a presentation on the tiered assessment for inhalation exposure, including available models and also some considerations for powder products. This presentation included some case studies which illustrated how the tiered approach could be applied.

Overall summary

- A tiered exposure assessment approach allows for step-by-step refinement of exposure, where higher tier approaches can overturn an initial unfavourable safety assessment outcome.
- For local lung effects, consideration of air concentration only does not take into account species differences in exposure and the industrial approach is to assess
local lung effects based on local metrics in the target such as lung surface area \((\text{mg/cm}^2)\) or lung weight \((\text{mg/g lung})\).

The proposed approach for cosmetic powders will require understanding of the risk of forming aerosols during use.

The SCCS stressed that models should consider the compound volatility instead of assuming instant 100% mixing of non-gaseous compounds in air.

- Dr. Tanja Hansen (from Fraunhofer ITEM) made a presentation on hazard identification and how the data for local side effects and respiratory tract is addressed.
  There is no perfect "one for all" solution but one needs to select the best model.
  The method presented is not yet validated.
  SCCS highlighted that it is more concerned about false negatives than false positives in chemical gases in \textit{vitro} - \textit{in vivo} correlation studies.

Quantitative \textit{in vitro} to \textit{in vivo} extrapolation is under research.
SCCS stressed that it is important to highlight that it is only the start of research and that no specific feedback is needed as SCCS is interested to know what can be taken on board in the new revision of the Notes of Guidance.

-> This session can be a basis for another exchange of views in the future when considerable progress has been made.
Developments foreseen by the industry could also be of interest to the SCCS.

4. **INTERNAL session (with SCCS members and external experts only)**

The revision of the SCCS Notes of Guidance on the testing of the cosmetic ingredients and their safety evaluation has started. Tasks have been distributed among members. It will be the 10th Revision in due course. It will be further discussed at the next meeting on 27 September. Clarifications on the legislative side have been requested to DG GROW.

5. **Update Information from Commission/Chair/Members**

- EURL ECVAM has launched a study to collect and describe non-animal methods being used for basic and applied research into neurodegenerative, respiratory tract and cardiovascular diseases, and breast cancer. Instructions to participate and guidance for the preparation of the required documents are available [here](#). Submission deadline: 18\textsuperscript{th} September 2017.

6. **Next steps**

To collect all input from the members related to the revision of the draft opinions and to prepare respective new versions for the next working group meeting (27 September 2017).
7. Next meetings
27 September and 14 December.

8. List of participants

SCCS Members
1. Dr Ulrike BERNAUER
2. Dr Laurent BODIN
3. Prof. Qasim CHAUDHRY  (Chair SCCS)
4. Prof. Pieter-Jan COENRAADS  (Vice-chair SCCS)
5. Prof. Maria DUSINSKA
6. Dr Janine EZENDAM
7. Prof. Corrado L. GALLI
8. Dr Berit GRANUM
9. Prof. Eirini PANTERI
10. Prof. Vera ROGIERS  (Vice-chair SCCS and chair of the WG)
11. Dr Christophe ROUSSELLE
12. Prof. Tamara VANHAECCKE

SCCS External expert
13. Dr Natalie VON GOETZ

External experts
14. Dr. Anthony BOWDEN (Unilever and representative of Cosmetics Europe)
15. Dr. Tanja HANSEN (Fraunhofer-Institute for Toxicology and Experimental Medicine - ITEM)

Observers
16. Dr Rob TAALMANN (Science & Research Director Cosmetics Europe)
17. Dr Matthias VEY (IFRA Scientific Director)

Apologies
18. Dr Leonardo CELLENO (SCCS member)
19. Dr Alain SIMONNARD (SCCS external expert)
20. Dr Renate KRATKE (SCHEER member)

SCCS Secretariat (DG SANTE C2)
21. Natacha GRENIER